Mylan launches generic schizophrenia, bipolar disorder drug

Alaric DeArment

4/24/2012

PITTSBURGH — Mylan has launched a generic drug for treating psychiatric disorders, the company said Tuesday.

Mylan announced the launch of olanzapine tablets in the 2.5-mg, 5-mg, 7.5-mg, 10-mg, 15-mg and 20-mg strengths.

The drug, a generic version of Eli Lilly's Zyprexa, is used to treat schizophrenia and bipolar disorder. Various versions of the drug had sales of about $3.3 billion in 2011, according to IMS Health.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Walgreens buyout reportedly could result in three divisions

Walgreens’ three core segments—U.S. pharmacy retailer Walgreens, U.K.-based Boots and specialty unit Shields Health Solutions—could become three independent divisions, per a report.

Sycamore Partners reportedly working on financing to acquire Walgreens

A potential buyout reportedly would include terms loans, a bridge loan and asset-based lending.

Ulta Beauty sets date for experiential beauty event

Ulta Beauty World will take place on April 26 in San Antonio, Texas.

CVS Health to open smaller format stores

Each location will average less than 5,000 square feet and will feature a full-service pharmacy with limited over-the-counter products available for purchase.

Walgreens reportedly close to roughly $10B deal to go private

The deal could be finalized by Thursday, per a WSJ report.